drugset / Trial / NCT03387774
Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients
Phase 3
Completed
179 enrolled
Sun Yat-sen University
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · collabFifth Affiliated Hospital, Sun Yat-Sen University · collabFirst People's Hospital of Foshan · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 3, open-label, multicenter, randomized controlled phase III clinical trial. The purpose of this study is to evaluate the efficacy of ulinastatin, a kind of protease inhibitor, in the treatment of radiation-induced acute oral mucositis in localregionally advanced nasopharyngeal carcinoma(NPC) patients treated with concurrent chemoradiotherapy(CCRT). To Explore a new and efficient way to reduce the incidence and severity of radiation-induced acute oral mucositis.
Timeline
- Start
- 2018-01-30
- Primary completion
- 2021-12-28
- Completion
- 2024-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulinastatin | Protein / enzyme biologic | — | Intravenous |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |